Dascena, a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, announced it raised $50 million in Series B funding led by Frazier Healthcare Partners with participation from Longitude Capital, existing investor Euclidean Capital, and an undisclosed investor. This round of funding will enable Dascena to advance a suite of machine learning algorithms to inform patient care strategies and improve outcomes. And Dascena algorithms have been validated through eighteen peer-reviewed publications in several studies funded by the National Institutes of Health and the National Science Foundation. According to a randomized controlled trial of hospitalized patients in the intensive care unit (ICU), Dascena's InSight algorithm resulted in a 58% reduction in patient mortality and a 21% reduction in length of hospital stay. And data from this prospective study of InSight were published in the BMJ Open Respiratory Research in 2017.